Collection and preservation of cord blood for personal use
Collection and preservation of cord blood for personal use
复制标题
DOI：
10.1016/j.bbmt.2007.11.005
复制
发表时间：
2008-03-01
影响因子：
4.3
通讯作者：
Lane, Thomas A.
中科院分区：
文献类型：
--
作者：
Ballen, Karen K.;Barker, Juliet N.;Lane, Thomas A.
无血缘关系的脐带血(CB)是一种有用的替代造血干细胞来源的患者没有合适的匹配和容易获得的亲属或无血缘关系的干细胞捐献者。今天，准父母可以选择将CB捐赠给公共CB银行，或者将CB保留并存储在私人银行，以备将来使用。替代方案通常被称为公共银行和私人银行。代表美国血液和骨髓移植学会(ASBMT)，我们回顾了目前可用的数据和意见，并提出以下建议：1.在可能的情况下，鼓励公众捐献脐带血。使用自己的CB的可能性非常小--很难量化，但在生命的头20年可能低至0.04%(1：2500)至0.0005%(1：200,000)--因此，不建议储存供个人使用的CB。家庭成员银行(为家庭成员收集和存储CB)是推荐的，当有兄弟姐妹患有可以通过异基因移植成功治疗的疾病时。只有当父母之间有共同的人类白细胞抗原时，才建议家庭成员代表患有可以通过异基因移植成功治疗的疾病的父母进行银行存款。委员会承认未来CB适应症的扩展潜力，并建议定期审查这些建议。(C)2008年美国血液和骨髓移植学会。
Unrelated-donor umbilical cord blood (CB) is a useful alternative hematopoietic stem cell source for patients without suitably matched and readily available related or unrelated stem cell donors. Expectant parents today may have the option of either donating the CB to a public CB bank or keeping and storing the CB in a private bank for potential use in the future. The alternatives are often referred to as public banking and private banking. On behalf of the American Society of Blood and Marrow Transplantation (ASBMT), we have reviewed the currently available data and opinions and offer the following recommendations:1. Public donation of CB is encouraged where possible.2. The probability of using one's own CB is very small-difficult to quantify but probably as low as 0.04% (1:2500) to 0.0005% (1:200,000) in the first 20 years of life-and therefore, storage of CB for personal use is not recommended.3. Family member banking (collecting and storing CB for a family member) is recommended when there is a sibling with a disease that may be treated successfully with allogeneic transplant. Family member banking on behalf of a parent with a disease that may be treated successfully with allogeneic transplant is only recommended when there are shared HLA-antigens between the parents.The committee acknowledges the expanding potential of indications for CB in the future, and suggests review of these recommendations at regular intervals. (C) 2008 American Society for Blood and Marrow Transplantation.